Targeted therapy using nanotechnology: Focus on cancer

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 467-483

  Sanna, Vanna ^a   Pala, Nicolino ^a   Sechi, Mario ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

BIND 014; Cancer; Nanomedicine; Targeted nanoparticles

Indexed keywords

ACCURINS; ANTINEOPLASTIC AGENT; APTAMER; ASPARAGINASE MACROGOL; BIKDD PLASMID DNA; BIND 014; CAMPTOTHECIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; IRINOTECAN; LIGAND; LIPOSOME; MITOPODOZIDE; MONOCLONAL ANTIBODY; NANOPARTICLE; OXALIPLATIN; PACLICAL; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEPTIDE DERIVATIVE; PLASMID DNA; PROLINDAC; PROTEIN DERIVATIVE; PROTEIN P53; SMALL INTERFERING RNA; THERMODOX; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; DELAYED RELEASE FORMULATION; TAXOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL ADENOCARCINOMA; GLIOBLASTOMA; GLIOMA; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; REVIEW; SOLID TUMOR; STOMACH ADENOCARCINOMA; STOMACH CANCER; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; MEDICINAL CHEMISTRY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TRENDS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; HUMANS; LIPOSOMES; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; TAXOIDS;

EID: 84892601165     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S36654     Document Type: Review

References (135)

1. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010;363(25):2434-2443.
2. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
3. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769.
4. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed Engl. 2009;48(5):872-897.
5. Doane TL, Burda C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem Soc Rev. 2012;41(7):2885-2911.
6. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-171.
7. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-782.
8. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
9. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-627.
10. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161(2):175-187.
11. Jain KK. Role of nanobiotechnology in the development of personalized medicine. Nanomedicine (Lond). 2009;4(3):249-252.
12. Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev. 2012;64(13): 1363-1384.
13. Gindy ME, Prud'homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv. 2009;6(8):865-878.
14. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62(11):1052-1063.
15. Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm. 2010;7(6):1899-1912.
16. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Appl Biochem Biotechnol. 2011;165(7-8):1628-1651.
17. Yoo D, Lee JH, Shin TH, Cheon J. Theranostic magnetic nanoparticles. Acc Chem Res. 2011;44(10):863-874.
18. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012;41(7):2656-2672.
19. Bae KH, Chung HJ, Park TG. Nanomaterials for cancer therapy and imaging. Mol Cells. 2011;31(4):295-302.
20. Taylor A, Wilson KM, Murray P, Fernig DG, Levy R. Long-term tracking of cells using inorganic nanoparticles as contrast agents: are we there yet? Chem Soc Rev. 2012;41(7):2707-2717.
21. Villalonga-Barber C, Micha-Screttas M, Steele BR, Georgopoulos A, Demetzos C. Dendrimers as biopharmaceuticals: synthesis and properties. Curr Top Med Chem. 2008;8(14):1294-1309.
22. Clift MJ, Stone V. Quantum dots: an insight and perspective of their biological interaction and how this relates to their relevance for clinical use. Theranostics. 2012;2(7):668-680.
23. Yamashita T, Yamashita K, Nabeshi H, et al. Carbon nanomaterials: efficacy and safety for nanomedicine. Materials. 2012;5(2):350-363.
24. Partha R, Conyers JL. Biomedical applications of functionalized fullerene-based nanomaterials. Int J Nanomedicine. 2009;4:261-275.
25. Kaur R, Badea I. Nanodiamonds as novel nanomaterials for biomedical applications: drug delivery and imaging systems. Int J Nanomedicine. 2013;8:203-220.
26. Klumpp C, Kostarelos K, Prato M, Bianco A. Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta. 2006;1758(3):404-412.
27. Zhu S, Xu G. Single-walled carbon nanohorns and their applications. Nanoscale. 2010;2(12):2538-2549.
28. Sperling RA, Rivera-Gil P, Zhang F, Zanella M, Parak WJ. Biological applications of gold nanoparticles. Chem Soc Rev. 2008;37(9): 1896-1908.
29. Cai W, Gao T, Hong H, Sun J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl. 2008;1:17-32.
30. Lal S, Clare SE, Halas NJ. Nanoshell-enabled photothermal cancer therapy: impending clinical impact. Acc Chem Res. 2008;41(12): 1842-1851.
31. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl. 2010;49(19):3280-3294.
32. Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev. 2012;41(7):2740-2779.
33. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238-252.
34. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
35. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
36. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;263(5580):797-800.
37. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263(5153):1600-1603.
38. Langer R. Drug delivery and targeting. Nature. 1998;392(Suppl 6679): 5-10.
39. Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle tech-nologies for cancer therapy. Handb Exp Pharmacol. 2010;(197):55-86.
40. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res. 2011;44(10):1123-1134.
41. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev. 2012;41(7):2780-2799.
42. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-515.
43. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003;55(3):403-419.
44. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv. 2004;1(4):321-333.
45. Betancourt T, Byrne JD, Sunaryo N, et al. PEGylation strategies for active targeting of PLA/PLGA nanoparticles. J Biomed Mater Res A. 2009;91(1):263-276.
46. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond). 2011;6(4): 715-728.
47. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49(36):6288-6308.
48. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
49. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
50. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419-436.
51. US Food and Drug Administration. Drugs. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed November 5, 2013.
52. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm. 2009;379(2):201-209.
53. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794-7803.
54. Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J Chemother. 2011;23(2):59-66.
55. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377-1397.
56. Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41(7): 2545-2561.
57. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev. 2013;42(3):1147-1235.
58. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41(7):2971-3010.
59. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473-480.
60. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006;2(12):689-700.
61. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387-6392.
62. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284.
63. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
64. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 2011;63(8):623-639.
65. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46(1-3):149-168.
66. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653-664.
67. Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nanodevice (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev. 2011;63(3):152-160.
68. Valle JW, Armstrong A, Newman C, et al. A phase 2study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs. 2011;29(5):1029-1037.
69. Matsumura Y, Hamaguchi T, Ura T, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004;91(10):1775-1781.
70. Tong R, Cheng J. Anticancer polymeric nanomedicines. Polym Rev (Phila Pa). 2007;47(3):345-381.
71. Singer JW. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J Control Release. 2005;109(1-3):120-126.
72. Young C, Schluep T, Hwang J, Eliasof S. CRLX101 (formerly IT-101)-a novel nanopharmaceutical of camptothecin in clinical development. Curr Bioact Compd. 2011;7(1):8-14.
73. Clinical Trials. gov. Study of paclitaxel in patients with ovarian cancer. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00989131. Accessed November 5, 2013.
74. Tagami T, Ernsting MJ, Li SD. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J Control Release. 2011;152(2):303-309.
75. Seetharamu N, Kim E, Hochster H, Martin F, Muggia F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res. 2010;30(2):541-545.
76. Clinical Trials. gov. A Phase I trial of nanoliposomal CPT-11 (NL CPT-11) in patients with recurrent high-grade gliomas. Available from: http://clinicaltrials.gov/show/NCT00734682. Accessed November 5, 2013.
77. Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129-139.
78. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-1626.
79. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750-763.
80. Canton I, Battaglia G. Endocytosis at the nanoscale. Chem Soc Rev. 2012;41(7):2718-2739.
81. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377-380.
82. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release. 2005;102(1):191-201.
83. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res. 2010;27(12):2569-2589.
84. Deckers R, Moonen CT. Ultrasound triggered, image guided, local drug delivery. J Control Release. 2010;148(1):25-33.
85. Gu F, Langer R, Farokhzad OC. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol. 2009;544:589-598.
86. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315-6320.
87. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008;105(7):2586-2591.
88. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010;27(7): 286-298.
89. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5(2):147-159.
90. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220-233.
91. Nobs L, Buchegger F, Gurny R, Allemann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem. 2006;17(1):139-145.
92. Weiner LM, Adams GP. New approaches to antibody therapy. Oncogene. 2000;19(53):6144-6151.
93. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346(6287):818-822.
94. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505-510.
95. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537-550.
96. Xiao Z, Farokhzad OC. Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS Nano. 2012;6(5):3670-3676.
97. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A. 2003;100(26):15416-15421.
98. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64(21):7668-7672.
99. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869-876.
100. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5(10):2674-2681.
101. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528-539.
102. Schulke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A. 2003;100(22):12590-12595.
103. Chou LY, Ming K, Chan WC. Strategies for the intracellular delivery of nanoparticles. Chem Soc Rev. 2011;40(1):233-245.
104. Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010;107(3):1235-1240.
105. Brissette R, Prendergast JK, Goldstein NI. Identification of cancer targets and therapeutics using phage display. Curr Opin Drug Discov Devel. 2006;9(3):363-369.
106. Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328(5981):1031-1035.
107. Chan JM, Zhang L, Tong R, et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A. 2010;107(5):2213-2218.
108. Talekar M, Kendall J, Denny W, Garg S. Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anticancer Drugs. 2011;22(10):949-962.
109. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54(5):675-693.
110. Liang C, Yang Y, Ling Y, Huang Y, Li T, Li X. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorg Med Chem. 2011;19(13):4057-4066.
111. Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52(2):347-357.
112. Byun Y, Mease RC, Lupold SE, Pomper MG. Recent development of diagnostic and therapeutic agents targeting glutamate carboxypeptidase II (GCPII). In: Supuran CT, Winum JY, editors. Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications. New York, NY: Binghe Wang Wiley Series in Drug Discovery and Development; 2009.
113. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov. 2005;4(12):1015-1026.
114. Sanna V, Pintus G, Roggio AM, et al. Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. J Med Chem. 2011;54(5):1321-1332.
115. Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther. 2008;7(6):974-982.
116. Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4(128):128ra139.
117. Wijagkanalan W, Kawakami S, Hashida M. Glycosylated carriers for cell-selective and nuclear delivery of nucleic acids. Front Biosci (Landmark Ed). 2011;16:2970-2987.
118. Hashida M, Nishikawa M, Yamashita F, Takakura Y. Cell-specific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev. 2001;52(3):187-196.
119. Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 2004;15(3):517-525.
120. ClinicalTrials. gov. Safety study of infusion of SGT-53 to treat solid tumors. Available from: http://clinicaltrials.gov/show/ NCT00470613. Accessed November 5, 2013.
121. ClinicalTrials. gov. Study of MBP-426in patients with second line gastric, gastroesophageal, or esophageal adenocarcinoma. from: http://clinicaltrials.gov/show/NCT00964080. Accessed November 5, 2013.
122. Sankhala KK, Mita AC, Adinin R, et al. A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J Clin Oncol. 2009;27:S2535.
123. ClinicalTrials. gov. Safety study of CALAA-01 to treat solid tumor cancers. Available from: http://clinicaltrials.gov/show/NCT00689065. Accessed November 5, 2013.
124. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009;6(3):659-668.
125. TrialsUnited. A Phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors. Available from: http://www.trialsunited.com/studies/NCT01702129.
126. Mamot C, Ritschard R, Vogel B, et al. A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors. J Clin Oncol. 2011;29(15):S3029.
127. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994;344(8932):1267-1272.
128. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6(4):229-239.
129. Zhang L, Zhang N. How nanotechnology can enhance docetaxel therapy. Int J Nanomedicine. 2013;8:2927-2941.
130. Gref R, Luck M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-313.
131. ClinicalTrials. gov. A study of BIND-014given to patients with advanced or metastatic cancer. Available from: http://clinicaltrials.gov/show/NCT01300533. Accessed November 5, 2013.
132. Baker J, Ajani J, Scotte F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009;13(1):49-59.
133. Von Hoff DD, Mita M, Eisenberg P, et al. A Phase 1study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, in patients with refractory solid tumors. Abstract LB-203 presented at the annual meeting of the American Association for Cancer Research, April 6-10, 2013, Washington, DC, USA.
134. ClinicalTrials. gov. A Phase 2study to determine the safety and efficacy of BIND-014 (docetaxel nanoparticles injectable suspension) as second line therapy to patients with non-small cell lung cancer. Available from: http://clinicaltrials.gov/show/NCT01792479. Accessed November 5, 2013.
135. ClinicalTrials. gov. A Phase 2study to determine the safety and efficacy of BIND-014 (docetaxel nanoparticles injectable suspension), administered to patients with metastatic castration-resistant prostate cancer. Available from: http://clinicaltrials.gov/show/NCT01812746. Accessed November 5, 2013.